FDA Approves Rozlytrek to Treat Certain Patients With an NTRK Gene Fusion and NSCLC
August 16th 2019The Food and Drug Administration approved Rozlytrek (entrectinib) for adult and adolescent patients 12 years of age and older whose cancers have the NTRK gene fusion and for adults with non-small cell lung cancer whose tumors are ROS1-positive and have spread to other parts of the body.